ライフサイエンスコーパス: ATGAM

1 ed with antilymphocyte therapy (5 OKT3 and 5 ATGAM).

2 PTLD or CMV disease at 5 years compared with Atgam.

3 0.007) were higher with Thymoglobulin versus Atgam.

4 mprovement) from thymoglobulin compared with Atgam.

5 ntial induction protocol with either OKT3 or Atgam.

6 requent early leukopenia than induction with Atgam.

7 -driven proliferation were reduced 30-60% by ATGAM.

8 d after the first year with Thymoglobulin or Atgam (13% vs. 33%, P=0.056).

9 Group III received Atgam 15 mg/kg on day 0 and began OKT3 on day 1.

10 14 days of Thymoglobulin (1.5 mg/kg/ day) or Atgam (15 mg/kg/day).

11 53 QALYs gained (3.68 thymoglobulin vs. 3.15 Atgam; 16.7% improvement) from thymoglobulin compared wi

12 s frequently with Thymoglobulin (17%) versus Atgam (36%) (P=0.011).

13 was higher with thymoglobulin compared with Atgam (48% vs. 29%; P=0.011).

14 atment biopsy results (Thymoglobulin 65% and Atgam 50%; P=0.15) were not statistically different.

15 enia was more common with Thymoglobulin than Atgam (56% vs. 4%; P<0.0001) during induction.

16 erior with Thymoglobulin (94%) compared with Atgam (63%; P=0.0005).

17 cally lower with thymoglobulin compared with Atgam (8% vs. 21%, P=NS).

18 ercentage of baseline (Thymoglobulin 72% and Atgam 80%; P=0.43), and improvement in posttreatment bio

19 in had a higher rejection reversal rate than Atgam (88% versus 76%, P=0.027, primary end point).

20 graft survival rates (Thymoglobulin 94% and Atgam 90%, P=0.17), day 30 serum creatinine levels as a

21 in (a rabbit-derived polyclonal antibody) to Atgam (a horse-derived polyclonal antibody) for inductio

22 -human thymocyte globulin, was compared with Atgam, a horse anti-human thymocyte globulin for the tre

23 to 21-day course of murine (OKT3) or equine (ATGAM) antilymphocyte treatment.

24 At the dosage administered in this study, ATGAM appears ineffective in improving the skin and pulm

25 lymphoproliferative disorder (PTLD) with the Atgam arm and none with Thymoglobulin.

26 er or cytomegalovirus disease, compared with Atgam at 10 years.

27 rus disease was less with Thymoglobulin than Atgam at 6 months (10% vs. 33%; P=0.025).

28 and received a single course of intravenous ATGAM, at a dosage of 10 mg/kg over 4 hours, on 5 consec

29 andomized to antithymocyte globulin therapy (ATGAM, ATG) received 15 mg/day i.v. within 48 hr of tran

30 ATGAM binding and receptor expression were determined by

31 ned more effectively with Thymoglobulin than Atgam both at the end of therapy (P=0.001) and at day 30

32 Two patients receiving ATGAM developed grade III-IV rejection at 3 weeks.

33 and anti-rejection treatment with 14 days of ATGAM followed by 6 days of OKT3 therapy for biopsy-prov

34 The first four cases were induced with ATGAM for 7 to 10 days.

35 double-blinded trial of Thymoglobulin versus Atgam for induction therapy in renal transplantation rev

36 obulin group and there were two cases in the Atgam group.

37 Thymoglobulin was found to be superior to Atgam in reversing acute rejection and preventing recurr

38 Simultaneous engagement by ATGAM in the context of allogeneic or mitogenic stimulat

39 mong patients randomized to thymoglobulin or Atgam induction in a single center, randomized, double-b

40 safety and efficacy of Thymoglobulin versus Atgam induction through 5 years.

41 nsplanted between 1993 and 1998 who received Atgam induction via peripheral vein.

42 -4; 15 mg/kg equine anti-thymocyte globulin (ATGAM) IV on days -1, +1, and +3; and thymic irradiation

43 Cytokines and ATGAM levels were measured by enzyme-linked immunosorben

44 pothesis that anti-human thymocyte globulin (ATGAM)-mediated immunosuppression is delivered via nonde

45 In vivo studies confirmed significant ATGAM-mediated inhibition of proliferative responses.

46 induction therapy with polyclonal antibody, ATGAM (n=127) or Thymoglobulin (n=71), from December 1,

47 lobulin (n=48) at 1.5 mg/kg intravenously or Atgam (n=24) at 15 mg/kg intravenously, intraoperatively

48 tion alone and 80% (4/5) in the tacrolimus + ATGAM/OKT3 group.

49 ction only; 5 transplants, oral tacrolimus + ATGAM/OKT3 induction.

50 arted at day 1-8 in the 5 patients receiving ATGAM/OKT3 induction.

51 recipients received antithymocyte globulin (ATGAM or thymoglobulin) as induction therapy or to treat

52 patients after polyclonal antibody therapy (ATGAM or thymoglobulin).

53 ticosteroids equine antilymphocyte globulin (ATGAM), or the mouse anti-human CD3 monoclonal antibody

54 tion was less severe with Thymoglobulin than Atgam (P=0.02).

55 ed with Thymoglobulin compared with 33% with Atgam (P=NS).

56 was lower in Thymoglobulin recipients versus ATGAM recipients (33% vs. 50%, P=0.02).

57 as higher in Thymoglobulin recipients versus ATGAM recipients (8% vs. 3%, P=0.002).

58 Mean follow-up was 90+/-25 months for ATGAM recipients and 32+/-15 months for Thymoglobulin re

59 Flow cytometry showed that ATGAM recognized multiple cell surface receptors and res

60 ATGAM recognizes and cross-links multiple cell surface r

61 rejection was lower with Thymoglobulin than Atgam (relative risk=0.09; P=0.009).

62 lin throughout the study (P<0.007), but with Atgam, significant lymphocyte reductions occurred only a

63 ATGAM synergized with phorbol myristate acetate to produ

64 cy of basiliximab to polyclonal anti-T-cell (ATGAM) therapy for the prevention of acute rejection in

65 Supernatant interleukin (IL)-2 levels in ATGAM-treated cultures were significantly reduced (P<0.0

66 rienced acute rejection compared with 25% of Atgam-treated patients (P=0.014).

67 ATGAM-treated T cells showed significant dose-dependent

68 Effectors raised after ATGAM treatment failed to develop cytotoxicity.

69 steroid and antilymphocyte antibody (OKT3 or ATGAM) unresponsive rejections in patients on CsA-based

70 open pilot study of antithymocyte globulin (ATGAM; Upjohn, Kalamazoo, MI) in 10 patients with early

71 We have safely administered equine ATG (Atgam) via peripheral veins since 1978.

72 ant recipients receiving their first dose of ATGAM were evaluated for proliferative responses and cel